Document ID: chunk:federal_register_of_legislation:F2024C01086:clause:1_15900
Version: federal_register_of_legislation:F2024C01086
Segment Type: clause
Provision Reference: sch 1 cl 15900
Character Range: 915590–916945

15900                                                 Breast, malignant tumour, targeted intraoperative radiation therapy, using an Intrabeam® or Xoft® Axxent® device, delivered at the time of breast‑conserving surgery (partial mastectomy or lumpectomy) for a patient who:                                                                                                               284.75
                                                      (a) is 45 years of age or over; and
                                                      (b) has a T1 or small T2 (less than or equal to 3 cm in diameter) primary tumour; and
                                                      (c) has a histologic grade 1 or 2 tumour; and
                                                      (d) has an oestrogen‑receptor positive tumour; and
                                                      (e) has a node negative malignancy; and
                                                      (f) is suitable for wide local excision of a primary invasive ductal carcinoma that was diagnosed as unifocal on conventional examination and imaging; and
                                                      (g) has no contra‑indications to breast irradiation
                                                      Applicable once per breast per lifetime (H)
Subgroup 2—Megavoltage